New understanding about gastropathy associated with using of nonsteroidal anti-inflammatory drugs
- Authors: Maev I.V1, Andreev D.N1, Dicheva D.T1, Zhilyaev E.V2,3
-
Affiliations:
- A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation
- Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
- European Medical Center
- Issue: Vol 19, No 8 (2017)
- Pages: 110-115
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/94936
- ID: 94936
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
I. V Maev
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federationакад. РАН, д-р мед. наук, проф., зав. каф. пропедевтики внутренних болезней и гастроэнтерологии ФГБОУ ВО «МГМСУ им. А.И.Евдокимова», засл. врач РФ, засл. деятель науки РФ 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
D. N Andreev
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation
Email: dna-mit8@mail.ru
канд. мед. наук, ассистент каф. пропедевтики внутренних болезней и гастроэнтерологии ФГБОУ ВО «МГМСУ им. А.И.Евдокимова» 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
D. T Dicheva
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federationканд. мед. наук, доц. каф. пропедевтики внутренних болезней и гастроэнтерологии ФГБОУ ВО «МГМСУ им. А.И.Евдокимова» 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
E. V Zhilyaev
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation; European Medical Centerд-р мед. наук, проф. каф. ревматологии ФГБОУ ДПО РМАНПО, глав. врач АО ЕМС, гл. внештатный специалист-ревматолог Департамента здравоохранения г. Москвы 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1; 123104, Russian Federation, Moscow, Spiridonevskii per., d. 5, str. 1
References
- Singh G. Gastrointestinal complications of prescription and over - the - counter nonsteroidal anti - inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther 2000; 7 (2): 115-21.
- Маев И.В., Самсонов А.А., Андреев Д.Н. Гастропатии, индуцированные нестероидными противовоспалительными средствами: патогенетически обоснованные подходы к профилактике и терапии. Фарматека. 2016; 2: 49-54.
- Tannenbaum H, Bombardier C, Davis P, Russel A.S. An Evidence - based approach to prescribing nonsteroidal anti - inflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006; 33: 140-57.
- Lanas A, Chan F.K. Peptic ulcer disease. Lancet 2017 Feb 23. pii: S0140-6736(16)32404-7.
- Lanas A, Perez-Aisa M.A, Feu F et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005; 100 (8): 1685-93.
- Roth S.H. Nonsteroidal anti - inflammatory drug gastropathy. We started it - can we stop it? Arch Intern Med 1986; 146 (6): 1075-6.
- Sostres C, Gargallo C.J, Lanas A. Nonsteroidal anti - inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther 2013; 15 (Suppl. 3): S3.
- Melcarne L, García-Iglesias P, Calvet X. Management of NSAID-associated peptic ulcer disease. Expert Rev Gastroenterol Hepatol 2016; 10 (6): 723-33.
- Larkai E.N, Smith J.L, Lidsky M.D, Graham D.Y. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti - inflammatory drug use. Am J Gastroenterol 1987; 82 (11): 1153-8.
- Lanas Á, Carrera-Lasfuentes P, Arguedas Y et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti - inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol 2015; 13 (5): 906-12.e2.
- Lewis S.C, Langman M.J, Laporte J.R et al. Dose - response relationships between individual nonaspirin nonsteroidal anti - inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta - analysis based on individual patient data. Br J Clin Pharmacol 2002; 54 (3): 320-6.
- Castellsague J, Riera-Guardia N, Calingaert B et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta - analysis of observational studies (the SOS project). Drug Saf 2012; 35 (12): 1127-46.
- Bhala N, Emberson J, Merhi A et al. Vascular and upper gastrointestinal effects of non - steroidal anti - inflammatory drugs: meta - analyses of individual participant data from randomised trials. Lancet 2013; 382 (9894): 769-79.
- Gargallo C.J, Sostres C, Lanas A. Prevention and Treatment of NSAID Gastropathy. Curr Treat Options Gastroenterol 2014; 12 (4): 398-413.
- Маев И.В., Самсонов А.А., Андреев Д.Н. Болезни желудка. М.: ГЭОТАР-Медиа, 2015.
- De Ruiter J. Non - steroidal antiinflammatory drugs (NSAIDS). Principles of Drug Action 2002; 2: 1-25.
- Sostres C, Gargallo C.J, Arroyo M.T, Lanas A. Adverse effects of non - steroidal anti - nflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010; 24: 121-32.
- Zidar N, Odar K, Glavac D et al. Cyclooxygenase in normal human tissues - is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? Cell Mol Med B 2009; 13 (9): 3753-63.
- Laine L. Nonsteroidal anti - inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996; 6 (3): 489-504.
- Mitchell J.A, Akarasereenont P, Thiemermann C et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90 (24): 11693-7.
- Gudis K, Sakamoto C. The role of cyclooxygenase in gastric mucosal protection. Dig Dis Sci 2005; 50 (1): S16-S23.
- Konturek S.J, Konturek P.C, Pawlik T et al. Duodenal mucosal protection by bicarbonate secretion and its mechanisms. J Physiol Pharmacol 2004; 55: 5-17.
- Свинцицкий А.С. НПВП гастродуоденопатии у больных остеоартрозом: особенности диагностики, профилактики и лечения. Научно - практическая ревматология. 2002; 3: 26-31.
- Hudson N, Balsitis M, Everitt S, Hawkey C.J. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non - steroidal anti - inflammatory drugs. Gut 1993; 34 (6): 742-7.
- Vaananen P.M, Keenan C.M, Grisham M.B, Wallace J.L. Pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy. Inflammation 1992; 16 (3): 227-40.
- Andrews F.J, Malcontenti-Wilson C, O’Brien P.E. Effect of nonsteroidal anti - inflammatory drugs on LFA-1 and ICAM-1 expression in gastric mucosa. Am J Physiol 1994; 266 (4, part 1): G657-G664.
- Mc Cafferty D.M, Granger D.N, Wallace J.L. Indomethacin - induced gastric injury and leukocyte adherence in arthritic versus healthy rats. Gastroenterology 1995; 109 (4): 1173-80.
- Насонов Е.Л., Каратеев А.Е. Поражения желудка, связанные с приемом нестероидных противовоспалительных препаратов (часть I). Клин. мед. 2000; 3: 4-9.
- Fiorucci S, Antonelli E, Morelli A. Mechanism of non - steroidal anti - inflammatory drug - gastropathy. Digest Liver Dis 2001; 33 (Suppl. 2): S35.
- Маев И.В., Самсонов А.А., Андреев Д.Н. Инфекция Helicobacter pylori. М.: ГЭОТАР-Медиа, 2016.
- Huang J.Q, Sridhar S, Hunt R.H. Role of Helicobacter pylori infection and non - steroidal anti - inflammatory drugs in peptic - ulcer disease: a meta - analysis. Lancet 2002; 359 (9300): 14-22.
- Lim Y.J, Hong S.J. Helicobacter pylori infection in nonsteroidal anti - infl ammatory drug users. Korean J Gastroenterol 2014; 64 (2): 70-5.
- Malfertheiner P, Megraud F, O'Morain C.A et al. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Gut 2017; 66 (1): 6-30.
- Lanza F.L, Chan F.K, Quigley E.M. Practice Parameters Committee of the American College of Gastroenterology, Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104 (3): 728-38.
- Laine L. The role of proton pump inhibitors in NSAID - associated gastropathy and upper gastrointestinal symptoms. Rev Gastroenterol Dis 2003; 3 (4): S30-S39.
- Micklewright R, Lane S, Linley W et al. Review article: NSAIDs, gastroprotection and cyclo - oxygenase - II - selective inhibitors. Aliment Pharmacol Ther 2003; 17 (3): 321-32.
- Patrignani P, Tacconelli S, Capone M.L. Risk management profile of etoricoxib: an example of personalized medicine. Ther Clin Risk Management 2008; 4 (5): 983-97.
- Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non - steroidal antiinflammatory drugs: network meta - analysis. BMJ 2011; 342: 7086.
- Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343 (21): 1520-8.
- Schwartz J, Dallob A, Larson P et al. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. J Clin Pharmacol 2008; 48 (6): 745-54.
- Chan F, Lanas A, Scheiman J et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173-9.
- Goldstein J, Eisen G, Lewis B et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 3-13.
- Mattia C, Coluzzi F. COX-2 inhibitors: pharmacological data and adverse effects. Minerva Anesthesiology 2005; 71 (7-8): 461-70.
- Nguyen A, Chaiton A. Cyclooxygenase (COX-2) selective inhibitors: any better than NSAIDs? Can Fam Physician 2001; 47: 1398-400.
- Laine L. Proton pump inhibitor co - therapy with nonsteroidal anti - inflammatory drugs - nice or necessary? Rev Gastroenterol Dis 2004; 4 (Suppl. 4): S33-S41.
- Vergara M, Catalan M, Gisbert J.P et al. Meta - analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005; 21: 1411e18.
- Koch M. Non - steroidal anti - inflammatory drug gastropathy: clinical results with misoprostol. Ital J Gastroenterol Hepatol 1999; 31 (1): S54-S62.
- Silverstein F.E, Graham D.Y, Senior J.R et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti - inflammatory drugs. A randomized, double - blind, placebo - controlled trial. Ann Intern Med 1995; 123 (4): 241-9.
- Graham Y, White R.H, Moreland L.W et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 1993; 119 (4): 257-62.
- Iinuma S, Naito Y, Yoshikawa T et al. In vitro studies indicating antioxidative properties of rebamipide. Dig Dis Sci 1998; 43 (Suppl. 9): 35S-39S.
- Yoshida N, Yoshikawa T, Iinuma S et al. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci 1996; 41 (6): 1139-44.
- Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Exp Rev Gastroenterol Hepatol 2010; 4 (3): 261-70.
- Zhang S, Qing Q, Bai Y et al. Rebamipide helps defend against nonsteroidal anti - inflammatory drugs induced gastroenteropathy: a systematic review and meta - analysis. Dig Dis Sci 2013; 58 (7): 1991-2000.
- Kim J.H, Park S.H, Cho C.S et al. Preventive efficacy and safety of rebamipid in NSAD-indused toxicity. Gut Liver 2014; 8 (4): 371-79.
- Park S.H, Cho C.S, Lee O.Y et al. Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial-STORM STUDY. J Clin Biochem Nutr 2007; 40 (2): 148-55.
- Tozawa K, Oshima T, Okugawa T et al. A Randomized, Double - Blind, Placebo - Controlled Study of Rebamipide for Gastric Mucosal Injury Taking Aspirin With or Without Clopidogrel. Dig Dis Sci 2014; 59 (8): 1885-90.
- Suzuki T, Yoshida N, Nakabe N et al. Prophylactic effect of rebamipide on aspirin - induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution.J Pharmacol Sci 2008; 106 (3): 469-77.